Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Janssen Research & Development, LLC

Reviewed by TrialFinderData Editorial Team · Updated

15 clinical trials · 15 recruiting · INDUSTRY

Janssen Research & Development, LLC has 15 clinical trials registered on ClinicalTrials.gov, with 15 actively recruiting participants. The trials listed below cover 12 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Janssen Research & Development, LLC\'s Trial Portfolio

Janssen Research & Development, LLC is an industry sponsor — typically a pharmaceutical, biotechnology, or medical device company. Industry sponsors fund and run the largest share of registered trials in the United States and are subject to FDA registration requirements under the FDA Amendments Act (FDAAA 801) for most drug and device studies.

15 of Janssen Research & Development, LLC's 15 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Janssen Research & Development, LLC's research footprint spans Arthritis, Psoriatic (3 trials), Myasthenia Gravis (3), and Non-Muscle Invasive Bladder Neoplasms (2) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Janssen Research & Development, LLC's portfolio is weighted toward later-stage research — Phase 3 accounts for 27% of registered trials. Later-stage trials are the ones most likely to lead directly to FDA approval decisions, and they typically enroll the largest patient cohorts.

Trials by Janssen Research & Development, LLC

RECRUITINGPhase 1 / Phase 2NCT05379595

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or...

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of...

Sponsor: Janssen Research & Development, LLCEnrolling: 22520 locations
Advanced or Metastatic Colorectal Cancer
RECRUITINGPhase 1NCT07107230

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with...

Sponsor: Janssen Research & Development, LLCEnrolling: 3809 locations
Colorectal Neoplasms
RECRUITINGPhase 1NCT07295951

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically...

Sponsor: Janssen Research & Development, LLCEnrolling: 101 location
Acute Lymphoblastic LeukemiaAcute LeukemiasAcute Myeloid Leukemia
RECRUITINGNCT07309445

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer...

The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs...

Sponsor: Janssen Research & Development, LLCEnrolling: 1501 location
Non-Muscle Invasive Bladder Neoplasms
RECRUITINGPhase 1 / Phase 2NCT05316155

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical...

Sponsor: Janssen Research & Development, LLCEnrolling: 23520 locations
Non-Muscle Invasive Bladder Neoplasms
RECRUITINGPhase 4NCT05201781

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and...

Sponsor: Janssen Research & Development, LLCEnrolling: 29520 locations
Multiple Myeloma
RECRUITINGPhase 1NCT07615426

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With...

The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and...

Sponsor: Janssen Research & Development, LLCEnrolling: 648 locations
Schizophrenia
RECRUITINGPhase 3NCT07577856

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to...

Sponsor: Janssen Research & Development, LLCEnrolling: 6446 locations
Colitis, Ulcerative
RECRUITINGPhase 3NCT06807424

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive...

The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active...

Sponsor: Janssen Research & Development, LLCEnrolling: 75020 locations
Arthritis, Psoriatic
RECRUITINGNCT07220824

A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting

The purpose of this study is to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with...

Sponsor: Janssen Research & Development, LLCEnrolling: 20020 locations
Arthritis, Psoriatic
RECRUITINGPhase 2NCT07321873

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic...

The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis...

Sponsor: Janssen Research & Development, LLCEnrolling: 24020 locations
Arthritis, Psoriatic
RECRUITINGPhase 3NCT04951622

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the...

Sponsor: Janssen Research & Development, LLCEnrolling: 19920 locations
Myasthenia Gravis
RECRUITINGPhase 2 / Phase 3NCT05265273

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (\<) 18 years of age (globally)...

Sponsor: Janssen Research & Development, LLCEnrolling: 1219 locations
Myasthenia Gravis
RECRUITINGPhase 3NCT07217587

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's...

Sponsor: Janssen Research & Development, LLCEnrolling: 11514 locations
Myasthenia Gravis
RECRUITINGPhase 2NCT02354014

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of...

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and anti-mycobacterial activity of bedaquiline...

Sponsor: Janssen Research & Development, LLCEnrolling: 6011 locations
Tuberculosis, Multidrug-Resistant

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Janssen Research & Development, LLC have on ClinicalTrials.gov?

Janssen Research & Development, LLC has 15 clinical trials registered on the federal ClinicalTrials.gov registry, of which 15 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Janssen Research & Development, LLC study?

Janssen Research & Development, LLC's registered trials cover 12 conditions on ClinicalTrials.gov, led by Arthritis, Psoriatic (3 trials), Myasthenia Gravis (3 trials), Non-Muscle Invasive Bladder Neoplasms (2 trials), advanced-or-metastatic-colorectal-cancer (1 trial), Colorectal Neoplasms (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Janssen Research & Development, LLC clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 15 trials tracked for Janssen Research & Development, LLC.